MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
MediWound reported its Q1 2024 financial results, highlighting $5 million in revenue, compared to $3.8 million in Q1 2023, with a forecast of $24 million for the year. Gross profit decreased to $0.6 million from $0.8 million due to revenue mix changes. MediWound's new manufacturing facility is on track for mid-2024 completion. The EscharEx® Phase III trial will start in H2 2024. Net loss widened to $9.7 million, driven by financial expenses related to warrant revaluation. The company joins the Russell 3000® Index and has $36 million in cash reserves as of March 31, 2024.
The NexoBrid® US launch is progressing, with 30 burn centers placing initial orders. FDA reviews and military contracts are expected to influence future results. R&D and SG&A expenses decreased due to phase completion and operational efficiencies.
- Q1 2024 revenue increased to $5 million, up from $3.8 million in Q1 2023.
- Forecasted revenue for 2024 is $24 million.
- New manufacturing facility on track for mid-2024 completion.
- EscharEx® Phase III trial to commence H2 2024.
- Company included in the preliminary list of the Russell 3000® Index.
- Operating loss decreased to $3.7 million from $4.4 million YoY.
- R&D expenses decreased to $1.5 million from $2.1 million YoY.
- SG&A expenses decreased to $2.9 million from $3.1 million YoY.
- NexoBrid® U.S. launch progressing, with 30 burn centers placing orders.
- Cash reserves of $36 million as of March 31, 2024.
- Gross profit decreased to $0.6 million, representing 12.2% of total revenue, from $0.8 million (21.7%) YoY.
- Net loss increased significantly to $9.7 million from $3.7 million YoY.
- Financial expenses from warrant revaluation amounted to $6.1 million.
- Cash and equivalents decreased to $36 million from $42.1 million as of December 31, 2023.
- Operating loss remains substantial at $3.7 million.
Insights
The first quarter financial results for MediWound reveal a mixed performance. The company reported revenue of
While the growth in revenue is positive, the significant net loss and decrease in gross margins from
Long-term prospects look promising given the impending completion of the new manufacturing facility and the initiation of the EscharEx® Phase III trial. This expansion could potentially improve operational efficiency and margins in the future.
The company’s inclusion in the Russell 3000® Index is also a positive indicator, likely to attract more institutional investors.
The announcement of the upcoming EscharEx® Phase III clinical trial is a significant milestone. EscharEx® aims to compete with SANTYL®, a well-established treatment in wound debridement. Phase II results showing EscharEx's superiority are promising and could disrupt the existing market if Phase III results are positive.
The continued progress in developing a temperature-stable formulation of NexoBrid® for use by the U.S. Army is another noteworthy development. This could open up a substantial market, given the need for non-surgical burn treatments in field conditions.
The interest in NexoBrid® from burn centers and hospitals in the U.S. indicates strong market acceptance. The expansion to more than 30 centers placing initial orders and over 60 centers progressing through Pharmacy and Therapeutics committee approvals highlight a successful market penetration strategy.
The company's strategy to collaborate with prominent wound care companies for the EscharEx® trial suggests a focused effort on leveraging existing market players to enhance trial success and eventual product adoption.
The forecasted revenue of
NexoBrid® interest surges;
Manufacturing facility on target for completion by mid-2024
EscharEx® Phase III study to launch 2H 2024
Company set to join Russell 3000® Index
Conference call today, May 29 at 8:30am Eastern Time
YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
"During the first quarter we maintained a laser-focused approach to executing our strategic plan. At the beginning of the year, we set three major goals: accelerate the revenue growth of NexoBrid®, complete construction of the new manufacturing facility by mid-year, and initiate the EscharEx® Phase III clinical trial in the second half of 2024, for which we have established collaborations with the most prominent wound care companies. I am pleased with our progress, as we are on track to achieve all of our targets," said Ofer Gonen, Chief Executive Officer of MediWound.
First Quarter 2024 Highlights, Recent Developments and Upcoming Milestones:
NexoBrid®
- U.S. launch by Vericel continued to progress. More than 60 burn centers completed submissions to Pharmacy and Therapeutics (P&T) committees, approximately 40 centers obtained approval, and more than 30 centers have placed initial product orders. Vericel noted significant increases in the number of patients treated with NexoBrid and the number of NexoBrid orders by both burn centers and hospitals.
- Construction of our new GMP-compliant, state-of-the-art manufacturing facility is on track to be completed by mid-2024, with commissioning set to begin in the third quarter of the year. The facility is expected to be fully operational in 2025, increasing the Company's manufacturing capacity sixfold.
- Supplemental BLA for pediatric indication accepted for review by the U.S. Food and Drug Administration (FDA). Decision expected in the second half of 2024.
- Development of the NexoBrid temperature-stable formulation for use as a non-surgical solution for field-care burn treatment for the U.S. Army is progressing as planned. FDA feedback on the development path is expected in the second half of 2024.
- Enrollment and 12-month follow-up for the Expanded Access Treatment Protocol (NEXT) have been concluded: 239 burn patients have been treated across 29 U.S. centers. Data readout is anticipated in the second half of 2024.
EscharEx®
- Phase III trial remains on track for final protocol submission in the first half of 2024. The global study aims to enroll 216 patients across 40 sites to be treated with either EscharEx or a gel vehicle placebo. An interim assessment will be performed once
67% of participants complete the trial. The study is expected to commence in the second half of 2024. - Recent Phase II data, which included comparative analyses demonstrating EscharEx’s superiority over SANTYL®, were presented at three prominent annual wound care conferences: the Wound Healing Society (WHS), the Symposium on Advanced Wound Care (SAWC), and the European Wound Management Association (EWMA).
Corporate Developments
- Company included in the preliminary list of the Russell 3000® Index, as part of the 2024 Russell indexes annual reconstitution.
First Quarter 2024 Financial Highlights
- Revenue: Revenue for the first quarter of 2024 was
$5.0 million , compared to$3.8 million in the first quarter of 2023. The increase is primarily attributed to revenue from Vericel and new contracts with the U.S. Department of Defense (DoD). - Gross Profit: Gross profit in the first quarter of 2024 was
$0.6 million , representing12.2% of total revenue, compared to$0.8 million , representing21.7% of total revenue in the first quarter of 2023. The decrease in gross margin is primarily due to changes in the revenue mix. - Expenditures:
- Research and Development: R&D expenses in the first quarter of 2024 were
$1.5 million , compared to$2.1 million in the first quarter of 2023. This decrease is primarily due to the completion of the EscharEx Phase II study. - Selling, General, and Administrative: SG&A expenses in the first quarter of 2024 were
$2.9 million , compared to$3.1 million in the first quarter of 2023.
- Research and Development: R&D expenses in the first quarter of 2024 were
- Operating Results: Operating loss in the first quarter of 2024 was
$3.7 million , compared to an operating loss of$4.4 million in the first quarter of 2023. - Net Loss: Net loss in the first quarter of 2024 was
$9.7 million , or$1.05 per share, compared to a net loss of$3.7 million , or$0.44 per share, in the first quarter of 2023. The increase in net loss is primarily due to financial expenses from revaluation of warrants, amounting to$6.1 million , driven by40% increase in the Company's share price. - Non-GAAP Adjusted EBITDA: Adjusted EBITDA for the first quarter of 2024 was a loss of
$2.9 million , compared to a loss of$3.4 million in the first quarter of 2023.
Balance Sheet Highlights
As of March 31, 2024, the Company had cash and cash equivalents, restricted cash, and deposits totaling
Conference Call
MediWound management will host a conference call for investors on Wednesday, May 29, 2024, beginning at 8:30 a.m., Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-833-630-1956 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-317-1837 (outside the U.S. & Israel). The call will be available via webcast by clicking HERE or on the Events & Presentations page of Company’s website.
A replay of the call will be available on the Company’s website at www.mediwound.com.
Non-IFRS Financial Measures
To supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company’s performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, one-time expenses, restructuring and share-based compensation expenses.
Although Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation, and when assessing the performance of our business with our senior management.
However, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for determining the Company’s operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the
For more information visit www.mediwound.com and follow the Company on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions. Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx® and NexoBrid®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.
These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.
| Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Media Contact: | |
| MediWound, Ltd. Unaudited Condensed Consolidated Statements of Financial Position | |||||
| | |||||
| March 31, | December 31, | ||||
| 2024 | 2023 | 2023 | |||
| CURRENT ASSETS: |
|
|
|
|
|
| Cash and cash equivalents and short-term deposits | 35,568 |
| 57,204 |
| 41,708 |
| Trade and other receivable | 5,317 |
| 3,531 |
| 5,141 |
| Inventories | 3,311 | 2,536 | 2,846 | ||
| Total current assets | 44,196 | 63,271 | 49,695 | ||
|
|
|
|
|
|
|
| Non-current assets |
|
|
|
|
|
| Trade and other receivables | 238 |
| 305 |
| 233 |
| Long-term restricted bank deposits | 446 |
| - |
| 440 |
| Property, plant and equipment, net | 10,422 | 3,724 | 9,228 | ||
| Right of use assets, net | 6,926 | 1,151 | 6,698 | ||
| Intangible assets, net | 149 | 215 | 165 | ||
| Total non-current assets | 18,181 | 5,395 | 16,764 | ||
|
|
|
| |||
| Total assets | 62,377 | 68,666 | 66,459 | ||
|
|
|
|
|
| |
| CURRENT LIABILITIES: |
|
|
|
|
|
| Current maturities of long-term liabilities | 1,541 | 2,139 | 1,410 | ||
| Warrants, net | 13,065 |
| 14,674 |
| 7,296 |
| Trade payables and accrued expenses | 4,246 | 3,403 | 5,528 | ||
| Other payables | 3,486 | 3,722 | 3,891 | ||
| Total current liabilities | 22,338 | 23,938 | 18,125 | ||
|
|
|
|
|
|
|
| :NON-CURRENT LIABILITIES |
|
|
|
|
|
| Liabilities in respect of IIA grants | 7,780 | 7,580 | 7,677 | ||
| Liabilities in respect of TEVA | 2,111 | 2,660 | 2,256 | ||
| Lease liabilities | 6,467 | 743 | 6,350 | ||
| Severance pay liability, net | 482 | 445 | 456 | ||
| Total non-current liabilities | 16,840 | 11,428 | 16,739 | ||
|
|
| ||||
| Shareholders' equity | 23,199 | 33,300 | 31,595 | ||
| Total liabilities & shareholder equity | 62,377 | 68,666 | 66,459 | ||
| MediWound, Ltd. Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss | |||||||
| | |||||||
| Three months ended |
|
| Year ended | ||||
| 2024 | 2023 |
|
| 2023 | |||
| Total Revenues | 4,964 | 3,799 |
|
| 18,686 | ||
| Cost of revenues | 4,357 | 2,973 |
|
| 15,108 | ||
| Gross profit | 607 |
| 826 |
|
| 3,578 | |
|
|
|
|
|
|
| ||
| Research and development | 1,470 |
| 2,102 |
|
| 7,467 | |
| Selling and Marketing | 1,179 |
| 1,106 |
|
| 4,844 | |
| General and administrative | 1,692 |
| 1,982 |
|
| 6,768 | |
| Other Income | - |
| - |
|
| (211) | |
| Operating loss | (3,734) | (4,364) |
|
| (15,290) | ||
|
|
|
|
|
|
|
| |
| Financial income (expenses), net | (5,971) | 676 |
|
| 8,759 | ||
| Taxes on income | (24) |
| (5) |
|
| (185) | |
| Net loss | (9,729) |
| (3,693) |
|
| (6,716) | |
| Foreign currency translation adjustments | 8 | (9) |
|
| (13) | ||
| Total comprehensive loss | (9,721) | (3,702) |
|
| (6,729) | ||
|
|
|
|
|
| |||
| Basic and diluted loss per share: |
|
|
|
|
|
| |
| Net loss per share | (1.05) | (0.44) |
|
| (0.75) | ||
| Weighted average number of ordinary shares | 9,234,104 | 8,388,109 |
|
| 9,013,144 | ||
| MediWound, Ltd. U.S. dollars in thousands | |||||
| | Three months ended |
| Year Ended | ||
| 2024 |
| 2023 |
| 2023 | |
| Cash Flows from Operating Activities: |
|
| |||
| Net loss | (9,729) | (3,693) |
| (6,716) | |
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
| |
|
|
|
|
|
|
|
| Adjustments to profit and loss items: |
|
|
|
| |
| Depreciation and amortization | 368 | 303 |
| 1,303 | |
| Share-based compensation | 512 | 619 |
| 1,940 | |
| Revaluation of warrants accounted at fair value | 6,080 |
| (932) |
| (8,310) |
| Revaluation of liabilities in respect of IIA grants | 233 | 259 |
| 427 | |
| Revaluation of liabilities in respect of TEVA | 107 | 122 |
| 468 | |
| Financing income and exchange differences of lease liability | 28 |
| (13) |
| 257 |
| Increase in severance liability, net | 35 | 77 |
| 83 | |
| Other income | - |
| - |
| (211) |
| Financial income, net | (513) | (246) |
| (2,231) | |
| Un-realized foreign currency loss | 67 | 345 |
| 189 | |
| 6,917 | 534 |
| (6,085) | ||
| Changes in asset and liability items: |
|
|
| ||
| Decrease (Increase) in trade receivables | (123) | 6,822 |
| 5,658 | |
| Increase in inventories | (448) | (583) |
| (906) | |
| Increase in other receivables | (115) | (313) |
| (894) | |
| Decrease in trade payables and accrued expenses | (1,370) |
| (1,948) |
| (594) |
| Increase (decrease) in other payables | 260 |
| (167) |
| (928) |
| (1,796) | 3,811 |
| 2,336 | ||
| Net cash provided by (used in) operating activities | (4,608) | 652 |
| (10,465) | |
|
|
|
| |||
| Unaudited Condensed Consolidated Statements of Cash Flows | |||||
| | |||||
| | Three months ended |
| Year Ended | ||
| | 2024 |
| 2023 |
| 2023 |
| Cash Flows from Investment Activities: |
|
| |||
| Purchase of property and equipment | (1,259) | (1,505) |
| (6,464) | |
| Interest received | 605 | 302 | | 1,947 | |
| Investment in short term bank deposits, net | (1,130) | (6,240) |
| (29,804) | |
| Net cash used in investing activities | (1,784) | (7,443) |
| (34,321) | |
| | | | | ||
| Cash Flows from Financing Activities: | |
|
|
| |
| Repayment of lease liabilities | (244) | (177) |
| (778) | |
| Proceeds from issuance of shares and warrants, and exercise of warrants, net | 499 |
| 25,157 |
| 24,909 |
| Repayments of IIA grants, net | (120) |
| (310) |
| (380) |
| Repayment of liabilities in respect of TEVA | (834) |
| (417) |
| (834) |
| Net cash provided by (used in) financing activities | (699) | 24,253 |
| 22,917 | |
|
|
|
|
|
| |
| Exchange rate differences on cash and cash equivalent balances | (89) | (337) |
| (160) | |
| Increase (decrease) in cash and cash equivalents | (7,180) | 17,125 |
| (22,029) | |
| Balance of cash and cash equivalents at the beginning of the period | 11,866 | 33,895 |
| 33,895 | |
| Balance of cash and cash equivalents at the end of the period | 4,686 | 51,020 |
| 11,866 | |
| MediWound Ltd. U.S. dollars in thousands | |||||
| Three months ended | Year ended | ||||
| 2024 |
| 2023 | 2023 | ||
| Net loss | (9,729) | (3,693) | (6,716) | ||
| Adjustments: |
|
|
| ||
| Financial income (expenses), net | (5,971) | 676 | 8,759 | ||
| Other Income, net | - |
| - |
| 211 |
| Taxes on income | (24) |
| (5) |
| (185) |
| Depreciation and amortization | (368) | (303) | (1,303) | ||
| Share-based compensation expenses | (512) | (619) | (1,940) | ||
| Total adjustments | (6,875) | (251) | 5,542 | ||
| Adjusted EBITDA | (2,854) | (3,442) | (12,258) | ||
FAQ
What was MediWound's revenue for Q1 2024?
What is MediWound's revenue forecast for 2024?
When will MediWound's new manufacturing facility be completed?
When will the EscharEx® Phase III trial start?
What was MediWound's net loss for Q1 2024?
How has the NexoBrid® U.S. launch progressed?
What are MediWound's cash reserves as of March 31, 2024?
What caused the increase in MediWound's net loss for Q1 2024?
What are MediWound's R&D expenses for Q1 2024?
Is MediWound included in any major stock index?
